JP6580552B2 - ４，４−二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用 - Google Patents

４，４−二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用 Download PDF

Info

Publication number
JP6580552B2
JP6580552B2 JP2016503019A JP2016503019A JP6580552B2 JP 6580552 B2 JP6580552 B2 JP 6580552B2 JP 2016503019 A JP2016503019 A JP 2016503019A JP 2016503019 A JP2016503019 A JP 2016503019A JP 6580552 B2 JP6580552 B2 JP 6580552B2
Authority
JP
Japan
Prior art keywords
independently
compound
alkyl
halogen
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519080A5 (enExample
JP2016519080A (ja
Inventor
ナラシムハチャリ ナラヤナン，
ナラシムハチャリ ナラヤナン，
Original Assignee
ビセン メディカル， インコーポレイテッド
ビセン メディカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビセン メディカル， インコーポレイテッド, ビセン メディカル， インコーポレイテッド filed Critical ビセン メディカル， インコーポレイテッド
Publication of JP2016519080A publication Critical patent/JP2016519080A/ja
Publication of JP2016519080A5 publication Critical patent/JP2016519080A5/ja
Application granted granted Critical
Publication of JP6580552B2 publication Critical patent/JP6580552B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
    • C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
JP2016503019A 2013-03-15 2014-03-14 ４，４−二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用 Active JP6580552B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798562P 2013-03-15 2013-03-15
US61/798,562 2013-03-15
PCT/US2014/029224 WO2014144702A2 (en) 2013-03-15 2014-03-14 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019103596A Division JP7018913B2 (ja) 2013-03-15 2019-06-03 ４，４－二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用

Publications (3)

Publication Number Publication Date
JP2016519080A JP2016519080A (ja) 2016-06-30
JP2016519080A5 JP2016519080A5 (enExample) 2017-04-20
JP6580552B2 true JP6580552B2 (ja) 2019-09-25

Family

ID=50631078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016503019A Active JP6580552B2 (ja) 2013-03-15 2014-03-14 ４，４−二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用
JP2019103596A Active JP7018913B2 (ja) 2013-03-15 2019-06-03 ４，４－二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019103596A Active JP7018913B2 (ja) 2013-03-15 2019-06-03 ４，４－二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用

Country Status (7)

Country Link
US (5) US9897604B2 (enExample)
EP (2) EP2970674B1 (enExample)
JP (2) JP6580552B2 (enExample)
CN (1) CN105339436B (enExample)
AU (1) AU2014228808C1 (enExample)
CA (1) CA2901000C (enExample)
WO (1) WO2014144702A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1934211T3 (en) 2005-09-02 2017-04-10 Visen Medical Inc Biocompatible N, N-disubstituted sulfonamide-containing fluorescent color markers
US9913917B2 (en) 2005-12-22 2018-03-13 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
EP2732826B1 (en) 2008-01-18 2017-11-08 Visen Medical, Inc. Fluorescent imaging agents
EP2707102B1 (en) 2011-05-09 2019-11-13 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
AU2014228504C1 (en) 2013-03-15 2019-10-03 Visen Medical, Inc. Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection
CN105339436B (zh) 2013-03-15 2018-05-25 文森医学公司 4,4-二取代环己基桥连七甲川花菁染料及其应用
JP7042254B2 (ja) 2016-08-11 2022-03-25 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 近赤外光開裂性コンジュゲートおよびコンジュゲート前駆体
CN107400080B (zh) * 2017-07-27 2020-03-31 中国科学院烟台海岸带研究所 一种基于花菁的有机化合物及其中间体的应用
JP2020050610A (ja) * 2018-09-27 2020-04-02 国立研究開発法人理化学研究所 バイオイメージング剤
CN109985252A (zh) * 2019-05-10 2019-07-09 南京鼓楼医院 一种新型双模态小分子造影剂及其制备方法与应用
CN110642839B (zh) * 2019-08-14 2022-04-01 深圳大学 一种纳米探针及其制备方法与应用
CN113045563A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种感蓝光谱增感剂的制备方法
CN112920171A (zh) * 2021-01-29 2021-06-08 南京邮电大学 一种含四嗪单元的花菁化合物及其制备方法和应用
CN113350336B (zh) * 2021-07-01 2022-06-10 中国人民解放军陆军军医大学 一种七甲川吲哚花菁或其衍生物的用途
CN115403503B (zh) * 2022-09-02 2023-05-26 中国药科大学 七甲川花菁素类染料偶联物、制法、药物组合物和应用
CN117169182B (zh) * 2023-08-30 2024-03-15 广州沙艾生物科技有限公司 一种干细胞治疗制剂体外效力检测方法及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219335A (en) 1978-09-18 1980-08-26 E. I. Du Pont De Nemours And Company Immunochemical testing using tagged reagents
US5571388A (en) * 1984-03-29 1996-11-05 Li-Cor, Inc. Sequencing near infrared and infrared fluorescense labeled DNA for detecting using laser diodes and suitable labels thereof
US6086737A (en) 1984-03-29 2000-07-11 Li-Cor, Inc. Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes and suitable labels therefor
JP2521702B2 (ja) * 1985-04-26 1996-08-07 株式会社リコー 光情報記録媒体
JPS6250187A (ja) * 1985-08-29 1987-03-04 Nippon Kayaku Co Ltd 耐光堅牢度向上法
JPS62103192A (ja) * 1985-10-30 1987-05-13 Olympus Optical Co Ltd 光情報記録媒体
JPS62103190A (ja) * 1985-10-30 1987-05-13 Olympus Optical Co Ltd 光情報記録媒体
JPS62124986A (ja) * 1985-11-27 1987-06-06 Mitsubishi Chem Ind Ltd 光学的記録媒体
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JP2732275B2 (ja) * 1989-01-20 1998-03-25 キヤノン株式会社 光学記録媒体
US5164297A (en) 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5445970A (en) 1992-03-20 1995-08-29 Abbott Laboratories Magnetically assisted binding assays using magnetically labeled binding members
JPH08501097A (ja) 1992-09-04 1996-02-06 ザ ゼネラル ホスピタル コーポレーション 臨床診断及び治療用部分を含む生体適合性ポリマー
US6593148B1 (en) * 1994-03-01 2003-07-15 Li-Cor, Inc. Cyanine dye compounds and labeling methods
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
JPH08234463A (ja) 1994-12-27 1996-09-13 Fuji Photo Film Co Ltd スキャニング露光を用いる画像形成方法
IT1276833B1 (it) 1995-10-09 1997-11-03 Sorin Biomedica Cardio Spa Coloranti fluorescenti della famiglia della solfo benz e indocianina
US5958667A (en) * 1996-07-24 1999-09-28 Agfa-Gevaert Photothermographic recording material comprising IR-sensitizing dyes
EP0821271B1 (en) 1996-07-24 2006-04-19 Agfa-Gevaert Process for preparing an Infra-red photothermographic material comprising a spectral sensitizer and a stilbene derivative supersensitizer and image recording method
DE69735697T2 (de) * 1996-07-24 2007-01-18 Agfa-Gevaert Verfahren zur Herstellung eines photothermographischen Infrarotmaterials, das einen Spektralsensibilisator und einen Stilbenderivat-Supersensibilisator enthält und ein Aufzeichnungsverfahren
JP3794793B2 (ja) * 1996-07-24 2006-07-12 アグフア−ゲヴエルト，ナームローゼ・フエンノートシヤツプ 増感色素を含むフオトサーモグラフイ記録材料及びそのための記録法
EP0821266A1 (en) 1996-07-24 1998-01-28 Agfa-Gevaert N.V. Photothermographic recording material comprising sensitizing dyes and a recording process therefor
US5876915A (en) 1996-07-24 1999-03-02 Agfa-Gevaert Photothermographic recording material comprising sensitizing dyes and a recording process therefor
US6027709A (en) * 1997-01-10 2000-02-22 Li-Cor Inc. Fluorescent cyanine dyes
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6046585A (en) 1997-11-21 2000-04-04 Quantum Design, Inc. Method and apparatus for making quantitative measurements of localized accumulations of target particles having magnetic particles bound thereto
JPH11185836A (ja) * 1997-12-16 1999-07-09 Fuji Photo Film Co Ltd 光電変換素子および光再生型光電気化学電池
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
ATE284433T1 (de) 1999-07-02 2004-12-15 Visen Medical Inc Fluorescierende cyaninlabels mit einem sulphamidobrückenglied
US7597878B2 (en) * 2000-09-19 2009-10-06 Li-Cor, Inc. Optical fluorescent imaging
JP4989013B2 (ja) * 2000-09-19 2012-08-01 リ−コール インコーポレーティッド シアニン色素
EP2325263B1 (en) 2000-09-29 2013-01-23 Life Technologies Corporation Modified carbocyanine dyes and their conjugates
WO2002038190A2 (en) 2000-10-27 2002-05-16 Beth Israel Deaconess Medical Center Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates
US7383076B2 (en) 2000-11-27 2008-06-03 The General Hospital Corporation Fluorescence-mediated molecular tomography
US6615063B1 (en) 2000-11-27 2003-09-02 The General Hospital Corporation Fluorescence-mediated molecular tomography
EP1209205A1 (en) 2000-11-28 2002-05-29 Innosense S.r.l. Improved process and method for the preparation of asymetric monofunctionalised indocyanine labelling reagents and obtained compounds
EP1213583A1 (en) 2000-12-06 2002-06-12 Innosense S.r.l. General method for the covalent immobilisation of indicators in, or onto a support useful for the fabrication of optical sensors
EP1221465A1 (en) 2001-01-03 2002-07-10 Innosense S.r.l. Symmetric, monofunctionalised polymethine dyes labelling reagents
US20030044353A1 (en) 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
AU2003207438A1 (en) 2002-01-02 2003-07-24 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
WO2003061711A2 (en) 2002-01-16 2003-07-31 Visen Medical, Inc. Chromophore probes for optical imaging
AU2003225763A1 (en) 2002-03-11 2003-09-29 Visen Medical, Inc. Optical imaging probes
EP2410315B1 (en) 2002-06-04 2020-04-01 Visen Medical, Inc. Imaging volumes with arbitrary geometries in contact and non-contact tomography
JP2004067816A (ja) * 2002-08-05 2004-03-04 Fuji Photo Film Co Ltd セルロースアシレートフィルム及びその製造方法、並びに該フィルムを用いた光学フィルム、液晶表示装置及びハロゲン化銀写真感光材料
JP2004083799A (ja) * 2002-08-28 2004-03-18 Fuji Photo Film Co Ltd セルロースアシレートフィルム及びその製造方法、並びに該フィルムを用いた光学フィルム、液晶表示装置及びハロゲン化銀写真感光材料
EP1593095B1 (en) 2003-02-05 2019-04-17 The General Hospital Corporation Method and system for free space optical tomography of diffuse media
WO2004108902A2 (en) 2003-06-04 2004-12-16 Visen Medical, Inc. Biocompatible fluorescent silicon nanoparticles
EP1824379B1 (en) 2004-12-08 2017-04-12 The General Hospital Corporation System and method for normalized fluorescence or bioluminescence imaging
US20060239916A1 (en) 2005-01-07 2006-10-26 Kai Licha Use of cyanine dyes for the diagnosis of proliferative diseases
ES2612738T3 (es) 2005-09-02 2017-05-18 Visen Medical, Inc. Agentes de formación de imágenes fluorescentes biocompatibles
WO2007028118A2 (en) 2005-09-02 2007-03-08 Visen Medical, Inc. Nicotinic acid and picolinic acid derived near-infrared fluorophores
DK1934211T3 (en) 2005-09-02 2017-04-10 Visen Medical Inc Biocompatible N, N-disubstituted sulfonamide-containing fluorescent color markers
US9913917B2 (en) 2005-12-22 2018-03-13 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
WO2007111669A2 (en) 2005-12-22 2007-10-04 Visen Medical, Inc. Combined x-ray and optical tomographic imaging system
ITSV20060002A1 (it) * 2006-01-19 2007-07-20 Ferrania Technologies Spa Colorante fluorescente di tipo cianinico
WO2007109364A2 (en) 2006-03-20 2007-09-27 The General Hospital Corporation Intramolecularly quenched fluorochrome conjugates and methods of use
JP5643514B2 (ja) 2007-02-09 2014-12-17 ビセン メディカル， インコーポレイテッド ポリシクロ染料およびその使用
WO2008109832A2 (en) 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
US8314406B2 (en) 2007-04-06 2012-11-20 The General Hospital Corporation Systems and methods for optical imaging using early arriving photons
US8492734B2 (en) 2007-10-19 2013-07-23 Visen Medical, Inc. Imaging systems featuring waveguiding compensation
WO2009078970A1 (en) 2007-12-14 2009-06-25 Biotium, Inc. Fluorescent compounds
EP2732826B1 (en) 2008-01-18 2017-11-08 Visen Medical, Inc. Fluorescent imaging agents
CA2715034C (en) 2008-03-14 2016-12-06 Visen Medical, Inc. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
AU2009228350B2 (en) 2008-03-25 2015-03-05 Visen Medical, Inc. Animal holder for in vivo tomographic imaging with multiple modalities
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
EP2428230A1 (en) * 2008-12-25 2012-03-14 Canon Kabushiki Kaisha Probe for auditory hair cells.
EP2470887B1 (en) 2009-08-28 2020-03-11 VisEn Medical, Inc. Systems for tomographic imaging in diffuse media using a hybrid inversion technique
US8401619B2 (en) 2009-09-22 2013-03-19 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
EP2707102B1 (en) 2011-05-09 2019-11-13 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
WO2013148319A1 (en) 2012-03-30 2013-10-03 Visen Medical, Inc. Bacterial imaging agents and methods of using same
CA2882019C (en) 2012-08-15 2021-02-09 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
JP6384821B2 (ja) * 2012-10-26 2018-09-05 国立大学法人三重大学 がん細胞阻害薬、がん幹細胞検出用プローブ
CN105339436B (zh) 2013-03-15 2018-05-25 文森医学公司 4,4-二取代环己基桥连七甲川花菁染料及其应用
AU2014228504C1 (en) 2013-03-15 2019-10-03 Visen Medical, Inc. Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection
WO2019067180A1 (en) * 2017-09-29 2019-04-04 Perkinelmer Health Sciences, Inc. NIR-SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION

Also Published As

Publication number Publication date
US11193932B2 (en) 2021-12-07
JP7018913B2 (ja) 2022-02-14
US10473658B2 (en) 2019-11-12
WO2014144702A3 (en) 2014-12-18
JP2019151665A (ja) 2019-09-12
AU2014228808C1 (en) 2018-12-20
AU2014228808A1 (en) 2015-08-27
JP2016519080A (ja) 2016-06-30
CA2901000A1 (en) 2014-09-18
US20140348746A1 (en) 2014-11-27
CA2901000C (en) 2023-03-14
EP2970674B1 (en) 2018-12-12
AU2014228808B2 (en) 2018-09-06
US20200049709A1 (en) 2020-02-13
CN105339436A (zh) 2016-02-17
US20180164312A1 (en) 2018-06-14
US20220178921A1 (en) 2022-06-09
CN105339436B (zh) 2018-05-25
WO2014144702A2 (en) 2014-09-18
US20240393330A1 (en) 2024-11-28
US9897604B2 (en) 2018-02-20
EP3489309A1 (en) 2019-05-29
EP2970674A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US20240393330A1 (en) 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof
JP6606487B2 (ja) ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素
JP5643514B2 (ja) ポリシクロ染料およびその使用
JP5416970B2 (ja) ニコチン酸及びピコリン酸誘導近赤外線蛍光団
JP2012224646A (ja) 生体適合性ｎ，ｎ−二置換スルホンアミド含有蛍光色素標識

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190603

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190828

R150 Certificate of patent or registration of utility model

Ref document number: 6580552

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250